This study is looking at whether a combination of two drugs, Iberdomide and Daratumumab, can help patients with multiple myeloma after they've had an autologous stem cell transplant (ASCT). The goal is to see if this treatment can effectively reduce or eliminate any remaining cancer cells (minimal residual disease, or MRD) and if it's a safe option. You might be able to join if you have multiple myeloma, have already received Daratumumab as part of your initial treatment, and have had an ASCT 90-150 days ago without your disease getting worse. The study aims to enroll 60 participants. The main way they'll measure success is by checking if your MRD is gone after 12 months.

Study design

This is an interventional study with a planned enrollment of 60 participants. It is a Phase 2 trial, meaning it's designed to assess the effectiveness and safety of the treatment.

What's involved

You would provide informed consent and complete screening assessments within 28 days before starting treatment. These assessments include specific laboratory tests and a medical evaluation.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 12 months, which suggests participants will be followed for at least that long to assess the rate of MRD negativity.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.